JP2020506695A5 - - Google Patents

Download PDF

Info

Publication number
JP2020506695A5
JP2020506695A5 JP2019540667A JP2019540667A JP2020506695A5 JP 2020506695 A5 JP2020506695 A5 JP 2020506695A5 JP 2019540667 A JP2019540667 A JP 2019540667A JP 2019540667 A JP2019540667 A JP 2019540667A JP 2020506695 A5 JP2020506695 A5 JP 2020506695A5
Authority
JP
Japan
Prior art keywords
composition
vector
raav
recombinant
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019540667A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020506695A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/015957 external-priority patent/WO2018140946A1/en
Publication of JP2020506695A publication Critical patent/JP2020506695A/ja
Publication of JP2020506695A5 publication Critical patent/JP2020506695A5/ja
Priority to JP2022169032A priority Critical patent/JP2023002715A/ja
Pending legal-status Critical Current

Links

JP2019540667A 2017-01-30 2018-01-30 糖原病を処置するための組換えウイルスベクター Pending JP2020506695A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022169032A JP2023002715A (ja) 2017-01-30 2022-10-21 糖原病を処置するための組換えウイルスベクター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762451963P 2017-01-30 2017-01-30
US62/451,963 2017-01-30
PCT/US2018/015957 WO2018140946A1 (en) 2017-01-30 2018-01-30 Recombinant virus vectors for the treatment of glycogen storage disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022169032A Division JP2023002715A (ja) 2017-01-30 2022-10-21 糖原病を処置するための組換えウイルスベクター

Publications (2)

Publication Number Publication Date
JP2020506695A JP2020506695A (ja) 2020-03-05
JP2020506695A5 true JP2020506695A5 (enExample) 2021-02-25

Family

ID=61274327

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019540667A Pending JP2020506695A (ja) 2017-01-30 2018-01-30 糖原病を処置するための組換えウイルスベクター
JP2022169032A Pending JP2023002715A (ja) 2017-01-30 2022-10-21 糖原病を処置するための組換えウイルスベクター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022169032A Pending JP2023002715A (ja) 2017-01-30 2022-10-21 糖原病を処置するための組換えウイルスベクター

Country Status (6)

Country Link
US (1) US20190367944A1 (enExample)
EP (1) EP3574104A1 (enExample)
JP (2) JP2020506695A (enExample)
AU (1) AU2018212002A1 (enExample)
CA (1) CA3050917A1 (enExample)
WO (1) WO2018140946A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113454226B (zh) * 2018-12-18 2025-10-31 阿尔特拉吉尼克斯制药公司 用于治疗糖原贮积病的方法和组合物
US20250222134A1 (en) * 2021-10-19 2025-07-10 University Of Connecticut Compositions and methods for the treatment of glycogen storage disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
KR100556864B1 (ko) 1997-05-13 2006-03-10 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 렌티바이러스-기원 유전자 전달 벡터
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
US6218186B1 (en) 1999-11-12 2001-04-17 Trustees Of The University Of Pennsylvania HIV-MSCV hybrid viral vector for gene transfer
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
RU2305708C2 (ru) 2001-10-02 2007-09-10 Энститю Клейтон Де Ля Решерш Рекомбинантный лентивирусный вектор, клетка-хозяин, трансдуцированная лентивирусным вектором, способ ее трансдукции и применение
EP1581056B1 (en) 2002-12-13 2010-07-21 Genetix Pharmaceuticals Inc. Therapeutic retroviral vectors for gene therapy
US20050261233A1 (en) * 2004-04-21 2005-11-24 Sanjay Bhanot Modulation of glucose-6-phosphatase translocase expression
WO2009019612A2 (en) 2007-08-03 2009-02-12 Institut Pasteur Lentiviral gene transfer vectors and their medicinal applications
WO2009097129A1 (en) 2008-01-29 2009-08-06 Applied Genetic Technologies Corporation Recombinant virus production using mammalian cells in suspension
WO2010114948A2 (en) 2009-04-02 2010-10-07 University Of Florida Research Foundation, Inc. An inducible system for highly efficient production of recombinant adeno-associated virus (raav) vectors
US20120133514A1 (en) 2009-06-30 2012-05-31 Asp Technology Aps Pause adviser system and use thereof
PT2529020T (pt) 2010-01-28 2018-07-30 Childrens Hospital Philadelphia Plataforma de fabrico escalável para purificação de vetor viral e vetores virais assim purificados para utilização na terapia génica
EP3074510B1 (en) * 2013-11-26 2018-08-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Adeno-associated virus vectors for treatment of glycogen storage disease
CA2972038C (en) * 2014-12-23 2023-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adeno-associated virus vectors encoding modified g6pc and uses thereof

Similar Documents

Publication Publication Date Title
JP2016538885A5 (enExample)
JP2024054426A5 (enExample)
Kaufmann et al. Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review
JP2014512171A5 (enExample)
Bobbin et al. RNA interference approaches for treatment of HIV-1 infection
JP2018501791A5 (enExample)
JP2010516252A5 (enExample)
JP2018523668A5 (enExample)
EP4272728A3 (en) Adeno-associated virus variant capsids and use for inhibiting angiogenesis
JP2018520997A5 (enExample)
JP2020514286A5 (enExample)
WO2019060454A3 (en) Adeno-associated virus variant capsids and methods of use thereof
Zhan et al. Vectored immunotherapeutics for infectious diseases: Can rAAVs be the game changers for fighting transmissible pathogens?
JP2019521139A5 (enExample)
CA3011874A1 (en) Methods and compositions for rna-guided treatment of hiv infection
WO2017197355A3 (en) Adeno-associated virus variant capsids and methods of use thereof
JP2020510447A5 (enExample)
JP2016537341A5 (enExample)
JP2019513794A5 (enExample)
JP2020518276A5 (enExample)
JP2018532428A5 (enExample)
CA3014631A1 (en) Excision of retroviral nucleic acid sequences
JP2019515914A5 (enExample)
JP2020518268A5 (enExample)
JP2018515101A5 (enExample)